DOSING USED IN PHASE 3 STUDIES In the most recent studies from the TRIUMPH programme (Phase 3) , retatrutide was administered as follows: Route: Subcutaneous Frequency: Once weekly Study duration: Approximately 68 weeks Phase 3 Schedule Recommended Dosage (Clinical Research Escalation Model) Retatrutide is administered once weekly using a gradual dose escalation to improve tolerability
Calories: 380410 Protein: 2832g GLP-1 Tip: Halve the amount of fruit if it feels to heavy
Mix with cosmetic products and apply on dry skin to prevent cakey makeup and get that natural, glowy look
Safety, Eligibility, and When to Discuss This with Your Provider GLP-1 medications carry known side effects including nausea, vomiting, and gastrointestinal distress
Individual results vary depending on factors such as age, lifestyle, consistency of use, and overall skincare habits
it also inhibits a number of enzymes that degrade connective tissue such as elastase, collagenase and hyaluronidase